Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|peds}} |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 20:28, 11 August 2023
| Section editor | |
|---|---|
 |
David Noyd, MD, MPH University of Washington Seattle, WA, USA |
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, fewer than 20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666